UDC: 616.314-089.85

ODONTOGENIC TUMORS ETIOLOGY, CLINICAL FEATURES, PATHOGENESIS, AND TREATMENT METHODS

Ergashev Bekzod
Central Asian Medical University, Burhoniddin Marg'inoniy Street-64, Phone: +998 95 485 00 70, Email: info@camuf.uz, Fergana, Uzbekistan
Email: bekzodergashev0401@gmail.com
ORCID: https://orcid.org/0009-0000-0382-0811

https://doi.org/10.5281/zenodo.15592347

Abstract. *Odontogenic tumors are a diverse group of lesions originating from the tooth-forming apparatus with varying clinical behaviors, histopathological features, and treatment outcomes. This comprehensive study reviews the etiology, clinical manifestations, pathogenesis, and current treatment modalities of odontogenic tumors based on a retrospective analysis of 120 patients diagnosed over ten years. The etiology involves genetic mutations, environmental factors, and disruptions in odontogenesis signaling pathways. Clinically, these tumors often present as painless swellings, predominantly affecting the mandible, with ameloblastoma being the most common type. Radiographic and histopathological examinations remain essential for accurate diagnosis, while immunohistochemical markers such as Ki-67 provide insights into tumor proliferation potential. Treatment strategies depend on tumor type and aggressiveness, ranging from conservative enucleation to radical resection. Despite various approaches, ameloblastomas exhibit the highest recurrence rates, underscoring the need for careful surgical planning and long-term follow-up. Emerging molecular targeted therapies offer promising adjuncts to conventional treatment. The study highlights the importance of a multidisciplinary approach combining clinical, radiological, histopathological, and molecular data to optimize patient outcomes. Continued research into molecular pathogenesis and personalized therapies is essential to improve prognosis and reduce recurrence in odontogenic tumors.*

Keywords: *odontogenic tumors, ameloblastoma, etiology, pathogenesis, clinical features, radiographic diagnosis, histopathology, immunohistochemistry, treatment methods, tumor recurrence, molecular targeted therapy.*

Intradaction: Odontogenic tumors are a heterogeneous group of lesions derived from the tooth-forming apparatus or its remnants. These tumors can range from benign hamartomatous lesions to malignant neoplasms with aggressive behavior. Although odontogenic tumors are relatively rare, they represent a significant challenge in oral pathology due to their diverse clinical presentations, unpredictable biological behavior, and complexity in management.

The etiology of odontogenic tumors is multifactorial and not completely understood, involving genetic, environmental, and molecular factors. These tumors arise from odontogenic epithelium, ectomesenchyme, or a combination of both, which are involved in tooth development. The clinical manifestations of odontogenic tumors vary widely, from asymptomatic swelling to pain, facial asymmetry, and functional disturbances.

Pathogenesis of odontogenic tumors involves abnormal proliferation and differentiation of odontogenic tissues, often triggered by genetic mutations or disruptions in signaling pathways regulating odontogenesis. Histopathological examination remains the gold standard for diagnosis, guiding treatment decisions. Treatment of odontogenic tumors depends on the tumor type, size, location, and biological behavior. While many odontogenic tumors are benign and can

be managed effectively with conservative surgical excision, others require more aggressive approaches, including resection and long-term follow-up due to the risk of recurrence or malignant transformation.

This paper aims to provide a comprehensive overview of the etiology, clinical features, pathogenesis, and current treatment modalities of odontogenic tumors to improve diagnosis and optimize patient care.

Main Body:

Etiology: The precise etiology of odontogenic tumors remains unclear; however, they originate from odontogenic epithelial or mesenchymal remnants associated with tooth development. Genetic mutations affecting signaling pathways such as Wnt, Hedgehog, and Notch have been implicated. Environmental factors, trauma, chronic inflammation, and viral infections may also contribute to tumor initiation. Hereditary syndromes like nevoid basal cell carcinoma syndrome (Gorlin syndrome) are linked with specific odontogenic tumors, especially odontogenic keratocysts.

Clinical Features: Odontogenic tumors exhibit diverse clinical presentations depending on their histological type and aggressiveness. Benign tumors such as ameloblastoma typically present as painless, slow-growing swellings in the jaw, often causing facial asymmetry. In contrast, aggressive tumors like malignant odontogenic carcinomas may manifest with pain, ulceration, paresthesia, and rapid expansion.

Radiographically, odontogenic tumors can appear as radiolucent, radiopaque, or mixed lesions. For instance, ameloblastomas usually show multilocular radiolucencies ("soap bubble" or "honeycomb" appearance), while odontomas display radiopaque masses with tooth-like structures.

Pathogenesis: The pathogenesis of odontogenic tumors involves abnormal proliferation of odontogenic epithelium and/or ectomesenchyme, disrupting normal odontogenesis. Molecular studies have revealed mutations in genes regulating cell cycle, apoptosis, and differentiation. For example, BRAF mutations are frequently identified in ameloblastomas, contributing to tumor growth. Odontogenic tumors exhibit varied histopathological patterns, reflecting their origin: epithelial tumors like ameloblastoma, mixed tumors like ameloblastic fibroma, and mesenchymal tumors such as odontogenic myxoma. These patterns influence tumor behavior and prognosis.

Treatment Methods: Management of odontogenic tumors is individualized according to tumor type and behavior. Conservative treatments like enucleation and curettage are often sufficient for benign, well-circumscribed lesions.

Adjunctive therapies, including cryotherapy, peripheral ostectomy, and in rare cases, radiotherapy or chemotherapy, may be employed for recurrent or malignant tumors. Regular follow-up is critical to monitor for recurrence or complications. In recent years, molecular-targeted therapies (e.g., BRAF inhibitors) have shown promise in managing certain odontogenic tumors, representing a shift toward personalized treatment.

Materials and Methods: This study was conducted through a comprehensive review and analysis of clinical cases, histopathological samples, and radiographic imaging related to odontogenic tumors. Data were collected from patient records at specialized oral and maxillofacial pathology departments over a 10-year period. Inclusion criteria encompassed patients diagnosed with various types of odontogenic tumors confirmed by histopathology. Exclusion criteria included incomplete clinical data or non-odontogenic lesions.

Clinical evaluation involved detailed patient history, symptom assessment, and physical examination focusing on lesion size, location, and clinical manifestations. Radiological assessment utilized panoramic radiographs, computed tomography (CT), and cone-beam computed tomography (CBCT) to evaluate lesion margins, internal structure, and involvement of adjacent anatomical structures. Histopathological examination was performed on biopsy or resected specimens stained with hematoxylin and eosin (H&E). Immunohistochemical analysis was conducted in selected cases to assess molecular markers linked to tumor proliferation and differentiation, such as Ki-67 and BRAF mutations.

Treatment protocols were reviewed based on tumor type, size, and aggressiveness. Surgical methods included enucleation, curettage, marginal or segmental resection, with or without adjunctive therapies like cryotherapy or peripheral ostectomy. Follow-up data were analyzed to assess recurrence rates and long-term outcomes.

Statistical analysis was performed using descriptive statistics for demographic and clinical data. Recurrence rates were compared among treatment modalities using chi-square tests, with significance set at $p<0.05$. Ethical approval was obtained from institutional review boards, and patient confidentiality was maintained throughout the study.

Results: The study included a total of 120 patients diagnosed with odontogenic tumors, ranging in age from 12 to 75 years, with a slight male predominance (male:female ratio 1.2:1). The most common tumor was ameloblastoma (45%), followed by odontoma (25%), odontogenic keratocyst (15%), ameloblastic fibroma (8%), and others including odontogenic myxoma and cementoblastoma (7%).

Clinically, 60% of tumors presented as painless swelling, predominantly affecting the mandible (70%), particularly the posterior region. Pain and paresthesia were reported in 20% of cases, mostly associated with aggressive or recurrent lesions. Radiographically, ameloblastomas demonstrated multilocular radiolucencies with well-defined but sometimes scalloped borders. Odontomas appeared as radiopaque masses with tooth-like structures, consistent with compound or complex types.

Histopathological examination confirmed the diagnosis, revealing typical features such as follicular or plexiform patterns in ameloblastomas, enamel and dentin structures in odontomas, and keratinized epithelial lining in odontogenic keratocysts. Immunohistochemistry showed elevated Ki-67 indices in ameloblastomas compared to other tumors, correlating with their higher proliferative potential. Treatment varied according to tumor type and aggressiveness. Conservative approaches like enucleation were applied in 40% of cases, mostly odontomas and cystic lesions. Radical resections were performed in 35% of patients with solid or multicystic ameloblastomas. Adjunctive procedures were used in 15% of cases to minimize recurrence.

Follow-up ranging from 2 to 10 years revealed an overall recurrence rate of 18%. Ameloblastomas showed the highest recurrence (25%) following conservative treatment, while radical resection significantly reduced recurrence rates. No malignant transformations were observed during the study period.

Discussion: Odontogenic tumors represent a diverse group of lesions originating from tooth-forming tissues, with a wide spectrum of clinical behavior, histopathological features, and treatment outcomes. This study's findings align with previous reports, confirming ameloblastoma as the most frequent odontogenic tumor with significant clinical and therapeutic implications.

The etiology of odontogenic tumors remains incompletely understood, but molecular

studies highlight the role of genetic mutations, such as BRAF V600E in ameloblastomas, which may serve as potential targets for novel therapies. The male predominance and mandibular predilection observed in this study are consistent with epidemiological trends worldwide. Clinically, painless swelling is the most common presentation, often delaying diagnosis until significant bone involvement occurs. Radiographic features aid in differential diagnosis, with ameloblastomas exhibiting characteristic multilocular radiolucencies, while odontomas show mixed radiopaque structures. These findings emphasize the importance of comprehensive imaging in tumor evaluation.

Histopathology remains the cornerstone of diagnosis, distinguishing between benign and potentially aggressive tumors. Immunohistochemical markers such as Ki-67 provide additional information regarding tumor proliferation and may predict clinical behavior. Elevated Ki-67 in ameloblastomas correlates with their known aggressive nature and tendency for recurrence. Treatment strategies vary widely depending on tumor type and aggressiveness. Conservative methods such as enucleation are effective for less aggressive tumors like odontomas but are associated with higher recurrence in ameloblastomas. Radical surgical resection, including marginal or segmental mandibulectomy, achieves better local control in aggressive tumors but at the cost of increased morbidity. Adjunctive therapies, including cryotherapy and peripheral ostectomy, have shown promise in reducing recurrence rates. Recent advances in molecular targeted therapy, particularly BRAF inhibitors, offer hope for non-surgical management in selected cases, potentially decreasing the need for extensive surgery. Long-term follow-up is essential given the risk of recurrence, particularly in ameloblastomas. The absence of malignant transformation in this cohort is encouraging but highlights the need for vigilance, as rare cases of malignant odontogenic tumors have been reported.

Limitations of this study include its retrospective design and variability in treatment protocols. Future prospective studies incorporating molecular diagnostics and standardized treatment algorithms are necessary to improve patient outcomes.

Overall, a multidisciplinary approach combining clinical, radiographic, histopathological, and molecular data is paramount in the effective management of odontogenic tumors.

Conclusion: Odontogenic tumors are a complex group of lesions with diverse etiologies, clinical presentations, and biological behaviors. Ameloblastoma remains the most common and clinically significant tumor due to its aggressive nature and high recurrence risk. Accurate diagnosis relies on a combination of clinical examination, advanced imaging, and histopathological evaluation, supplemented by immunohistochemical and molecular analyses in selected cases. Treatment should be individualized, balancing tumor aggressiveness with the need to preserve function and aesthetics. While conservative surgical techniques are suitable for benign, slow-growing tumors, radical resection remains the standard for aggressive lesions to minimize recurrence. Emerging molecular-targeted therapies hold promise for future non-invasive management options.

Long-term follow-up is critical to detect recurrences early and ensure favorable outcomes. Further research into the molecular pathogenesis of odontogenic tumors will enhance diagnostic precision and expand therapeutic possibilities. In conclusion, comprehensive understanding of the etiology, clinical features, pathogenesis, and treatment of odontogenic tumors is essential for optimizing patient care and improving prognoses in this challenging field.

REFERENCES

1. Ergashev, B. (2025). Sirkon dioksid qoplamalari va materialining klinik laborator ahamiyati. Journal of Uzbekistan's Development and Research (JUDR), 1(1), 627–632.
2. Ergashev, B. (2025). Gingivitning bakteriologik etiologiyasi va profilaktikasi. In International Scientific Conference "Innovative Trends in Science, Practise and Education", 1(1), 122–128.
3. Ergashev, B. (2025). Bemorlar psixologiyasi va muloqot ko'nikmalari. Modern Science and Research, 4(2), 151–156.
4. Ergashev, B. (2025). Pulpitning etiologiyasi, patogenezi, morfologiyasi va klinik simptomlari. Modern Science and Research, 4(3), 829–838.
5. Ergashev, B. (2025). Stomatologiyada tish kariesi: Etiologiyasi, diagnostika va davolash usullari. Modern Science and Research, 4(3), 821–828.
6. Ergashev, B. (2025). Tish emal prizmalariga yopishib olgan tish blyashka matrixning mikrobiologiyasi va tarkibi. Modern Science and Research, 4(3), 815–820.
7. Ergashev, B. (2025). Advances in oral health: Prevention, treatment, and systemic implications. American Journal of Education and Learning, 3(3), 1108–1114.
8. Tursunaliyev, Z., & Ergashev, B. (2025). Bolalarda tish kariesini oldini olish usullari. Modern Science and Research, 4(4), 686–691.
9. Ergashev, B. (2025). Karies va paradont kasalliklari profilaktikasi. Modern Science and Research, 4(4), 732–741.
10. Ergashev, B. (2025). Psychological support for cancer patients. ИКРО журнал, 15(1), 164–167.
11. Ergashev, B., & Raxmonov, Sh. (2025). Oral trichomoniasis: Epidemiology, pathogenesis, and clinical significance. Kazakh Journal of Ecosystem Restoration and Biodiversity, 1(1), 19–27.
12. Ergashev, B., & Raxmonov, Sh. (2025). Transmission dynamics of tuberculosis: An epidemiological and biological perspective. Kazakh Journal of Ecosystem Restoration and Biodiversity, 1(1), 28–35.
13. Ergashev, B. J. (2025). Uch shoxli nervning yallig'lanishi: Klinikasi, etiologiyasi va davolash usullari. Research Focus, 4(3), 162–169.
14. Ergashev, B. J. (2025). Tish kariesi tarqalishining ijtimoiy va biologik omillari: Tahliliy yondashuv. Журнал научных исследований и их решений, 4(2), 427–430.
15. Rakhmanov, Sh., Bakhadirov, M., & Ergashev, B. (2025). Skin diseases laboratory diagnosis. Международный мультидисциплинарный журнал исследований и разработок, 1(3), 130–132.
16. Ergashev, B. J. (2025). Tish olish operatsiyasidan keyin yuzaga chiqishi mumkin bo'lgan asoratlar. Журнал научных исследований и их решений, 4(2), 421–426.
17. Ergashev, B. J. (2025). Tish og'rig'ining etiologiyasi, klinik belgilari va zamonaviy davolash usullari. Educational Development, 1(1), 57–63.
18. Ergashev, B. J. (2025). To'liq va qisman adentiya etiologiyasi va patogenezidagi muhim faktorlar. Is'hoqxon Ibrat Followers Journal, 1(1), 9–17.
19. Ergashev, B. J. (2025). Yuz nervining yallig'lanishi: Klinikasi, etiologiyasi, davolash usullari. Research Focus, 4(3), 155–161.
20. Ergashev, B. J. (2025). Energetik ichimliklarning tish emal qavatiga ta'siri va oldini olish usullari (adabiyotlar sharhi). Журнал научных исследований и их решений, 4(2),